Fractional CDO, Small Molecule Parenteral

Reveal Pharmaceuticals; Massachusetts; Hybrid; USD 120,000 - 240,000; Part time

Job summary

Reveal Pharmaceuticals in Cambridge, MA seeks a Fractional Chief Development Officer (contract) to lead our Phase 2 lead asset and broader R&D pipeline. This builder role will guide strategy and execute cross-functional development efforts, with 10–20 hours per week initially and potential expansion for the right candidate.

The ideal candidate blends strategic vision with hands-on execution, collaborating across leadership, scientific founders, and external partners while advancing clinical,

Qualifications

• 15+ years of biopharmaceutical drug development experience.
• Executive leadership experience at the VP level or above.
• Experience leading small molecule and parenteral drug programs.
• Track record advancing programs from Phase 2 through NDA or regulatory submission.
• Experience spanning preclinical development through IND and early clinical development.
• Strong expertise in regulatory strategy, global drug development, and program management.
• Experience building and leading virtual teams, CROs, consultants, and external partners.

Responsibilities

• Lead development of the Phase 2 lead asset through late-stage clinical development and regulatory submission.
• Develop and execute integrated clinical, regulatory, CMC, and operational strategies and timelines.
• Guide clinical trial execution, CRO management, data review, and key development decisions.
• Create the development plan for Reveal’s fibrogenesis pipeline and lead its advancement.
• Build and lead a high-performing development organization using the optimal combination of employees, consultants, CROs, and advisors.
• Support strategic partnerships, fundraising, licensing, and corporate development activities.

Skills

Biopharmaceutical drug development

Executive leadership

Clinical development

Education

MD/PhD/PharmD or equivalent

Job description

Reveal Pharmaceuticals in Cambridge, MA seeks a Fractional Chief Development Officer (contract) to lead our Phase 2 lead asset and broader R&D pipeline. This builder role will guide strategy and execute cross-functional development efforts, with 10–20 hours per week initially and potential expansion for the right candidate.

The ideal candidate blends strategic vision with hands-on execution, collaborating across leadership, scientific founders, and external partners while advancing clinical,